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Myeloid Derived Suppressor Cells (MDSCs) heavily infil-
trate in a variety of solid tumors and suppress anti-tumor
T-cell activity. Our recent studies have demonstrated the
ability of monocytic, Ly6C+ MDSCs to promote glioma
growth through the activation of cyclooxygenase (COX)-2
pathway, which is responsible for prostaglandin-synthesis.
ONO-AE3-208 is an antagonist of the prostaglandin
E (EP)-4 receptor, which is an important positive feed-
back regulator of the COX-2 pathway. We thus examined
the ability of ONO-AE3-208 to suppress MDSC activity
in gliomas. ONO-AE3-208 treatment in mice bearing
established GL261-quad glioma in the brain resulted in
complete and persistent rejection of the tumors. Flow
cytometric analysis revealed that gliomas in the ONO-
AE3-208-treated mice were infiltrated by fewer numbers
of Ly6C+ MDSCs compared with non-treated animals.
We subsequently isolated glioma-infiltrating Ly6C+
MDSCs by flow-sorting to address their functions. RT-
PCR analysis revealed that the Ly6C+ MDSCs derived
from ONO-AE3-208 treated mice expressed lower levels
of the Arg1 and Cox2 expression compared to control
animals. Consistently, brain infiltrating leukocytes in
ONO-AE3-208 treated tumor-bearing mice demonstrated
enhanced IFN-g expression compared with control mice,
suggestive of enhanced T-cell activity. Importantly,
ONO-AE3-208 inhibited glioma growth and promoted
immune activity in 2 additional murine glioma models:
the Sleeping Beauty de novo glioma model and the
SB28 glioma cell line model. Our data demonstrate that
ONO-AE3-208 may be useful in the treatment of glioma
patients to suppress Ly6C+ MDSCs and promote anti-
tumor immunity.
Authors’ details
1University of California San Francisco, San Francisco, CA, USA. 2University of
Pittsburgh, Pittsburgh, PA, USA.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P217
Cite this article as: Kohanbash et al.: ONO-AE3-208 inhibits myeloid
derived suppressor cells and glioma growth. Journal for ImmunoTherapy
of Cancer 2014 2(Suppl 3):P217.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1University of California San Francisco, San Francisco, CA, USA
Full list of author information is available at the end of the article
Kohanbash et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P217
http://www.immunotherapyofcancer.org/content/2/S3/P217
© 2014 Kohanbash et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
